Business Wire

SES Supports Luxembourg at Expo 2020 in Dubai

Del

SES S.A. (Euronext Paris:SESG) (LuxX:SESG) announced today that it will support Luxembourg’s presence at Expo 2020 in Dubai. The world exhibition with the overall theme “Connecting Minds, Creating the Future” will take place between October 2020 and April 2021 in the United Arab Emirates. Its main theme will be developed through three spheres: Opportunity, Mobility and Sustainability. Focusing on Luxembourg’s strengths in economic and technological innovation and diversification, Luxembourg’s pavilion will explore the key topic “Resourceful Luxembourg”.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161219005792/en/

SES Supports Luxembourg at Expo 2020 in Dubai (Photo: Business Wire)

SES Supports Luxembourg at Expo 2020 in Dubai (Photo: Business Wire)

SES supports the Grand Duchy and the Luxembourg Ministry of the Economy alongside two other partners, the Luxembourg Chamber of Commerce and POST Luxembourg. The concept of the pavilion and the cooperation were presented today at a joint press-conference in the Luxembourg Ministry of the Economy.

Karim Michel Sabbagh, President and CEO of SES, commented: “SES is an excellent example of Luxembourg’s global reach. Covering 99% of the planet and connecting over a billion people every day, SES perfectly demonstrates how a small country can have an impact well beyond its frontiers and even reach the most remote corners of the world. SES also illustrates Luxembourg’s pioneering role in space technologies and its ambition to explore new resources. As a global leader and a strong partner of the Government, we enthusiastically participate in this new adventure and look forward to supporting Luxembourg’s presence in Dubai.”

Étienne Schneider, Luxembourg’s Deputy Prime Minister and Minister of the Economy, commented: “The United Arab Emirates are the most important commercial partner of Luxembourg in the Golf region. In promoting innovation and sustainable development, the profile of Expo 2020 perfectly aligns with our national approach of global economic diversification, especially with reference to the space sector and information and communication technologies. Dubai is the first Arab city in the world to host a universal expo that expects over 25 million visitors. Our participation offers a unique opportunity to highlight Luxembourg’s strengths on the international scene, and particularly in the Middle East.”

Follow us on:

Twitter: https://twitter.com/SES_Satellites

Facebook: https://www.facebook.com/SES.YourSatelliteCompany

YouTube: http://www.youtube.com/SESVideoChannel

Blog: https://www.ses.com/news/blogs

SES White papers are available under https://www.ses.com/news/whitepapers

About SES

SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in four key market verticals (Video, Enterprise, Mobility and Government). It provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions, and businesses worldwide. SES’s portfolio includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) television reach in Europe, and O3b Networks, a global managed data communications service provider. Another SES subsidiary, MX1, is a leading media service provider and offers a full suite of innovative digital video and media services. Further information available at: www.ses.com

Contact information

SES
Markus Payer
Corporate Communications
Tel. +352 710 725 500
Markus.Payer@ses.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 201711.12.2017 13:00Pressemelding

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients. “Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice

Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses11.12.2017 12:47Pressemelding

The Valence Group acted as lead financial advisor to SK Capital Partners on its announced acquisition of the Fire Safety and Oil Additives businesses of Israel Chemicals Ltd. (“ICL”) for approximately $1 billion. The transaction is expected to close during the first half of 2018. The Businesses, headquartered in St. Louis, Missouri, have global operations and are market leaders in each of their segments. The ICL Fire Safety business is a formulator and manufacturer of fire management chemicals. Its Phos-Chek fire retardants, Class A and B foams, and water enhancing gels are the world’s leading chemical solutions for managing wildland, military, industrial and municipal fires, and are used in partnership with fire management agencies across the globe. The ICL Oil Additives business provides high quality phosphorus pentasulfide used in the preparation of ZDDP-based lubricant additives, i

Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care11.12.2017 10:18Pressemelding

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005434/en/ Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4 Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,

Dr Amal Al Qubaisi Wins Parliamentarian Excellence Award as Best President of Arab Parliament11.12.2017 09:41Pressemelding

The Arab Inter-Parliamentary Union (AIPU) has honored Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the United Arab Emirates parliament, with the Parliamentarian Excellence Award in the Presidents of Arab Parliaments category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005411/en/ Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the UAE parliament (Photo: AETOSWire) The award honors Al Qubaisi as ‘first female leader of a parliament in the Arab world’, celebrating her achievements on a national, regional and global scale, as well as the accomplishments made by FNC under her leadership. It also acknowledges the pioneering parliamentarian initiatives, projects and programs she has spearheaded and her significant contr

Financial Market Regulator Grants EU Payment License to DIMOCO Payment Services11.12.2017 08:00Pressemelding

The Austrian Financial Market Authority (FMA) granted a license under the Payment Service Act to DIMOCO Payment Services . The awarded license allows DIMOCO Payment Services to contribute to the payment value chain, offering merchants a single technical interface and a unified clearing & settlement process for many payment methods, including credit cards, online bank transfers, SEPA and direct debit cards. “We differ from most PSPs in the global payments ecosystem with our personal touch,” said Boris Kersten, Managing Director of DIMOCO Payment Services. “We proactively and personally monitor the overall payment process. In addition to monitoring individual transactions, we make recommendations and take actions to decrease chargebacks and fraudulent transactions. This process is not simply left to algorithms, the human element is added to the mix resulting in the protec

Top UK university hospital unveils data that support the use of rapid infusion for Truxima® (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma11.12.2017 08:00Pressemelding

New data from University College London Hospitals NHS Foundation Trust (UCLH) on the safety and tolerability of rapid infusion of CT-P10 were presented this weekend at the 59th American Society of Hematology (ASH) Annual Meeting. The results showed that rapid infusion of CT-P10 was well-tolerated across all patient groups and patients could be safely switched from reference rituximab to CT-P10 without reverting to slower infusion rates1. The independent study examined the infusion-related reactions (IRRs) in three different patient groups: rituximab naive, those switching directly from reference rituximab to CT-P10, and those that received their last dose of reference rituximab at least 6 months prior to the study.1 The administration of rituximab is associated with IRRs which occur most frequently during the first infusion. To reduce the risk of IRRs, it is the man

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom